OncoPrecision Highlights Groundbreaking Advancements in Cancer Treatment
NEW YORK / OncoPrecision Corporation, a leader in developing innovative antibody-based cancer therapies, recently announced the oral presentation of critical data regarding its development candidate, ONC001. This presentation will take place at a prestigious annual event for hematology specialists and professionals.
ONC001 embodies a natural progression in addressing monocytic leukemia. As a pioneering antibody-drug conjugate (ADC), it has been meticulously designed to engage with CD64, a receptor that is predominantly expressed in chronic myelomonocytic leukemia (CMML) and specific acute myeloid leukemia (AML) subsets. This innovative strategy stems from OncoPrecision's advanced discovery engine, which merges extensive patient-derived data with state-of-the-art AI screening techniques, effectively pinpointing critical cellular vulnerabilities.
Dr. Gastón Soria, Co-Founder and Chief Scientific Officer, is set to unveil compelling preclinical data that underscores ONC001’s efficacy. His presentation will illuminate several key aspects:
Key Highlights From the Presentation
- Engagement of CMML and AML cells derived from actual patient samples.
- Remarkable activity exhibited in cases resistant to existing conventional therapies.
- Strong evidence of efficacy in various model types, showcasing both heterotopic and orthotopic effectiveness.
According to Tarek Zaki, Co-Founder and Chief Executive Officer, the recognition of ONC001 for this significant presentation marks a pivotal moment for OncoPrecision. "This ADC's development signifies our commitment to tackling the resistance mechanisms prevalent in aggressive blood cancers. We’re eager to present this work to the hematology community and engage with potential partners for strategic development," he emphasized.
Dr. Soria echoed this sentiment, noting that ONC001 is a notable achievement born from OncoPrecision's unique integration of patient biology insights with precise target identification and selection of ADC payloads. Despite the historical knowledge surrounding CD64 as a biomarker for monocytic leukemia, no current approved treatments have adequately leveraged it. Thus, ONC001 represents a significant breakthrough.
Upcoming Oral Presentation Details
Event Information
- Title: ONC001: A first-in-class ADC targeting CD64 for monocytic leukemia treatment.
- Presenter: Dr. Gastón Soria, Co-Founder & Chief Scientific Officer.
- Session: Molecular Pharmacology and Drug Resistance: New strategies for overcoming AML therapy resistance.
- Date: December 6, 2025.
- Session Time: 4:00 PM – 5:30 PM.
- Presentation Time: 5:15 PM – 5:30 PM.
- Location: Valencia Room, OCCC.
About OncoPrecision Corporation
OncoPrecision is revolutionizing oncology therapeutics through the integration of extensive patient-derived biology and advanced AI capabilities. By developing precision medicines, the company aims to significantly enhance the likelihood of clinical success. Its approach combines translational biology with advanced ADC engineering, thus creating a pipeline of top-tier therapeutic interventions across various cancers, including hematologic malignancies and solid tumors. Moreover, OncoPrecision is actively seeking collaborations to expedite the advancement and market entry of its innovative therapeutic programs.
Frequently Asked Questions
What is ONC001?
ONC001 is a first-in-class antibody-drug conjugate (ADC) specifically designed to target CD64, primarily found in certain leukemia subtypes.
What are the potential benefits of ONC001?
ONC001 aims to address treatment-resistant forms of blood cancer by directly targeting mechanisms of resistance, leading to improved patient outcomes.
Who will present the data on ONC001?
Dr. Gastón Soria, Co-Founder and Chief Scientific Officer of OncoPrecision, will present the data during the annual meeting.
Where will the presentation take place?
The presentation is scheduled for the Valencia Room at the Orlando Convention Center on December 6, 2025.
How does OncoPrecision utilize patient-derived biology?
OncoPrecision leverages insights from patient biology collections combined with AI to identify viable therapeutic targets and create effective treatments.
